https://www.selleckchem.com/pr....oducts/cd38-inhibito
Treatment of metastatic melanoma has dramatically improved in recent years, thanks to the development of immunotherapy and BRAF-MEK-targeted therapies. However, these developments revealed marked heterogeneity in patient response, which is yet to be fully understood. In this work, we aimed to associate the proteomic profiles of metastatic melanoma with the patient clinical information, to identify protein correlates with metastatic location and prior treatments. We performed mass spectrometry-based proteomic analysis of 185 met
Like
Comment
Share
